Lv1
50 积分 2024-07-11 加入
Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor
4个月前
已完结
Discovery and resistance mechanism of a selective CDK12 degrader
4个月前
已完结
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
4个月前
已完结
Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions
4个月前
已完结
Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy
4个月前
已完结
CDK inhibitors from past to present: A new wave of cancer therapy
4个月前
已完结
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
5个月前
已完结
Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
5个月前
已完结
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
5个月前
已完结
Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
5个月前
已完结
皖公网安备34019202002308
